Instructions for Authors 2018

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**Nomenclature and Abbreviations.** Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (http://www.gene.ucl.ac.uk/). Approved mouse nomenclature may be obtained from http://www.informatics.jax.org/. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXX (where XXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

**Ethical Policies and Standards.** ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html
In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

**Specific information and additional instructions for Authors**

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.

2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.

3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

6. Authors should pay attention to the following points when writing an article for AR:
   - The Instructions to Authors must be followed in every detail.
   - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
   - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
   - Results given in figures should not be repeated in tables.
   - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
   - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
   - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
   - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
   - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
   - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
   - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

9. Articles submitted to AR may be rejected without review if:
   - they do not fall within the journal's policy.
   - they do not follow the instructions for authors.
   - language is unclear.
   - results are not sufficient to support a final conclusion.
   - results are not objectively based on valid experiments.
   - they repeat results already published by the same or other authors before the submission to AR.
   - plagiarism is detected by plagiarism screening services.
   (Rejection rate (2016): 66%).

10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org

12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.
   (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2018 - International Institute of Anticancer Research (G.J. DCS). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
General Policy

IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models of biomedical research.

The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance.

Editorial Office: International Institute of Anticancer Research, 1st km Kaptanlidou-Kalamou Rd., P.O. Box 22, Kapaneriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 5389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIA R WEBSITES: www.iiar-anticancer.org and www.iiarjournals.org

International Journal of Experimental and Clinical Pathophysiology and Drug Research

Published bimonthly by the International Institute of Anticancer Research

Available online only and open access with Stanford University HighWire Press

Selection of Recent Articles


Morphological Distinction of Histiocytic Sarcoma from Other Tumor Types in Bernese Mountain Dogs and Flatoated Retrievers. S.A. ERICH, F. CONSTANTINO-CASAS, J.M. DOBSON, E. TESKE (Utrecht, The Netherlands; Cambridge, UK)

Tissue-directed Implantation Using Ultrasound Visualization for Development of Biologically Relevant Metastatic Tumor Xenografts. R.A. VAN NOO R D , T. TAMURA, H. TAK E SH IMA (Mannheim, Germany)

Effects of the Bis(4-hydroxyphenyl)-propionitrile on Induction of Polyovular Follicles in the Mouse Ovary. T. SATO, H. KIM, H. KAKUTA, T. IGUCHI (Yokohama, Japan)

Re-evaluation of Culture Condition of PC12 and SH-SY5Y Cells Based on Growth Rate and Amino Acid Consumption. H. SAKAGAMI, R. SUZUKI, Y. SHIRATAKI, S. IWAMA, M. NAKAGAWA, H. SUZUKI, K. TANAKA, N. TAMURA, H. TAKESHIMA (Sakado, Japan)

Clinical Impact of Rest Dual-Energy Computed Tomography Myocardial Perfusion in Patients with Coronary Artery Disease. S. BAUMANN, et al. (Mannheim, Germany)


Structures Improve Cellular Adhesion and Viability. P. HARTJEN, A. STEINER, R. WATCHEL, K. HERITZ, K. LEHMANN, H. HERZOG (Phoenix; Tempe, AZ, USA)

Comparison of the Grip Strength Using the Martin-Vigorimeter and the JAMAR-Dynamometer: Establishment of Normal Values. S. NEUMANN, S. KWI SDA, C. KRE TTEK, R. GAULKE (Hannover; Hamburg; Germany; Zurich, Switzerland)

Role for Neutrophil Extracellular Traps (NETs) and Platelet Aggregation in Early Septic-induced Hepatic Dysfunction. K. SAKURAI, T. MIYASHITA, et al. (Shikawa, Japan; Baltimore, MD, USA)

Netrin-4 Promotes Differentiation and Migration of Osteoblasts. Y. ENOKI, T. SATO, S. KOKUBA, N. HAYASHI, T. IWATA, M. YAMATO, M. USUI, M. MATSUMOTO, T. TODOMA, W. ARIYOSHI, T. NISHIHARA, T. YODA (Saitama; Fukuoka; Tokyo, Japan)

Early PET-CT After Stereotactic Radiotherapy for Stage I Non-small-cell Lung Carcinoma Is Predictive of Local Control. M. TYRAN, N. CHARRIE R, J. DARREON, A. MADROSZYK, A. TALLE T, N. SALE M (Marseille, France)
General Policy

CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal’s scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission.

CGP is published bimonthly by the International Institute of Anticancer Research (IIAR) and is available online only and open access with Stanford University HighWire Press. The IIAR is a member of UICC. For more information please visit our website www.cgp.iiarjournals.org.

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIAR WEBSITES: www.iiar-anticancer.org and www.iiarjournals.org

Selection of Recent Articles

The Role of micro RNAs in Breast Cancer Metastasis: Preclinical Validation and Potential Therapeutic Targets. U.H. WEIDLE, S. DICKOPF, C. HINTERMAIR, G. KOLLMORGEN, F. BIRZELE, U. BRINKMANN (Penzberg; Munich, Germany; Basel, Switzerland)

Transcriptomic Profiling of MDA-MB-231 Cells Exposed to Boswellia Serrata and 3-O-Acetyl-B-Boswellic Acid; ER/UPR Mediated Programmed Cell Death. M.A. ELIZABETH, L.A. CHARLES, SOLIMAN F.A. KARAM (Tallahassee, FL, USA)

Screening for Multiple Autoantibodies in Plasma of Patients with Breast Cancer. L. BASSARO, S.J. RUSSELL, E. PASTWA, S.A. SOMIARI, R.J. SOMIARI (Johnstown; Windber, PA, USA)


Regulation of β-Catenin Phosphorylation by PR55β in Adenoid Cystic Carcinoma. K. ISHIBASHI, K. ISHII, G. SUGIYAMA, Y. KAMATA, A. SUZUKI, W. KUMAMARU, O. OHYAMA, H. NAKANO, T. KIYOSHIMA, T. SUMIDA, T. YAMADA, Y. MORI (Fukuoka, Japan)

Admixture Mapping Links RACGAP1 Regulation to Prostate Cancer in African Americans. B.D. WILSON, L.J. RICKS-SANTI, T.E. MASON, M. ABBAS, R.A. KITTLES, G.M. DUNSTON, Y.M. KANAAN (Washington, DC; Hampton, VA; Duarte, CA, USA)

Consistent Involvement of Chromosome 13 in Angiolipoma. I. PANAGOPOULOS, L. GORUNOVA, K. ANDERSEN, I. LOBMAIER, B. BJERKEHAGEN, S. HEIM (Oslo, Norway)

Analysis of K-Ras Interactions by Biotin Ligase Tagging. C. RITCHIE, A. MACK, L. HARPER, A. ALFADHLI, P.J.S. STORK, X. NAN, E. BARKLIS (Portland, OR, USA)

CYP3A4 Gene Is a Novel Biomarker for Predicting a Poor Prognosis in Hepatocellular Carcinoma. R. ASHIDA, Y. OKAMURA, K. OSHISHIMA, Y. KAKUDA, K. UESAKA, T. SUGIURA, T. ITO, Y. YAMAMOTO, T. SUGINO, K. URAKAMI, M. KUSUHARA, K. YAMAGUCHI (Shizuoka; Tokyo, Japan)

A Phase I/II Study of NAC with Docetaxel, Cisplatin, and S-1 for Stage III Gastric Cancer. Y. TANAKA, C. KUNISAKI, Y. IZUMISAWA, H. MAKINO, J. KIMURA, S. SATO, H. MIYAMOTO, T. KOSAKA, H.A. ONO, M. TAKAHASHI, K. SATO, H. AKIYAMA, I. ENDO (Yokohama, Japan) ................................................................. 6016

Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site. F. THANGARAJAH, C. VOGL, C. PAHMEYER, C. EICHLER, J. HOLTSCHMIDT, D. RATIU, P. MALLMANN, W. MALTER (Cologne, Germany) .......... 6023

Retraction ................................................................................................................................................................. 6027

Detection of KK-LC-1 Protein, a Cancer/Testis Antigen, in Patients with Breast Cancer. Y. KONDO, T. FUKUYAMA, R. YAMAMURA, N. FUTAWATARI, Y. CHIKI, Y. TANAKA, Y. NISHI, Y. TAKAHASHI, H. YAMAZAKI, N. KOBUYASHI, M. WATANABE (Sagamihara; Kitamoto; Tokyo; Kitakyushu, Japan)............... 5923

Serum DHEA-S Is a Predictive Parameter of Abiraterone Acetate in Patients with Castration-resistant Prostate Cancer. K. SUZUKI, M. SAKAMOTO, T. TERAKAWA, J. FURUKAWA, K. HARADA, N. HINATA, Y. NAKANO, M. FUJISAWA (Kobe, Japan) ................................................................. 5929

Preexisting Interstitial Lung Disease and Lung Injury Associated with Irinotecan in Patients with Neoplasms. Y. OZAWA, K. KODA, D. AKAHORI, T. MATSUI, H. HASEGAWA, T. KAKUTANI, T. AMANO, M. TANAHASHI, H. NIWA, Y. KUNIMOTO, K. YAMADA, K. YOKOMURA, T. SUDA (Shizuoka; Wakayama, Japan) .................................................................................................................................................................... 5937

Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre. A. ATHAUDA, D. WATKINS, K. MOHAMMED, I. CHAU, N. STARLING, S. RAO, D. TAIT, K. AITKEN, D. CUNNINGHAM (Surrey, UK)................................................. 5943


Long-term Follow-up Results of CT-guided Daily Adaptive Radiation Therapy for Localized Prostate Cancer. Y. HAMA, T. KAJI (Tokyo; Saitama, Japan) ................................................................................................................. 5959

Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors. T. COLLOT, J.-D. FUMET, Q. KLOPFENSTEIN, J. VINCENT, L. BENGRIE, F. GHIRINGHELLI (Dijon, France) ............. 5963


Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial. M. SHINKAI, M. IMANO, Y. CHIBA, Y. HIRAKI, H. KATO, M. IWAMA, O. SHIRAISHI, A. YASUDA, M. TSUBAKI, S. NISHIDA, Y. KIMURA, T. YASUDA (Osaka, Japan) ........................................................................................................................................ 5975

EGFR, SMAD7, and TGFBR2 Polymorphisms Are Associated with Colorectal Cancer in Patients with Lynch Syndrome. A.B. KAMIZA, W.-C. WANG, J.-F. YOU, R. TANG, Y.-T. CHIEN, C.-H. LAI, L.-L. CHIU, T.-PI. LO, K.-Y. HUNG, C.-A. HIUNG, C.-C. YEH (Taipei; Taoyuan; Miaoli; Taichung, ROC) ......................... 5983

Investigation of Survivin Gene Polymorphism and Serum Survivin Levels in Patients with Brain Tumors. D. KAFADAR, I. YAYLIM, A.M. KAFADAR, C. CACINA, A. ERGEN, M.Y. KAYNAR, T. ISBIR (Istanbul, Turkey) ................................................................. 5991

Foamy Histiocyte-like Esophageal Adenocarcinoma: Unusual Morphology and Diagnostic Pitfalls. F. YIN, J. PIAO, X. LIU, J. LAI (Gainesville, FL; St. Louis, MO, USA)........................................................................................................ 5999

Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma. N. YOON, J. KIM, L.-S. MAENG, J.H. AHN, E.S. PARK (Incheon, Republic of Korea) ............. 6003

Contents continued on the preceding page
Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol. J. KENYON, W. LIU, A. DALGLEISH (Winchester Hants; London, UK) ........................................................ 5831


Cholangiocarcinoma: CT-guided High-Dose Rate Brachytherapy (CT-HDRBT) for Limited (<4 cm) and Large (>4 cm) Tumors. M. JONCZYK, F. COLLETTINI, D. SCHNAPAUFF, D. GEISEL, G. BÖNING, F. FELDHAUS, T. DENECE, G. WIENERS, B. HAMM, B. GEBAUER (Berlin, Germany) ............................ 5843

Impact of Body Mass Index (BMI) on Chemotherapy-associated Toxicity in Ovarian Cancer Patients. A Pooled Analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) Databank on 1,213 Patients. J.P. GRABOWSKI, R. RICHTER, H. RITTMESTER, R. CHEKEROV, H. WOOPEN, J. SEHOULI (Berlin, Germany) ......................................................................................................................................................... 5853

Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer. K. SUGIYAMA, Y. NARITA, S. MITANI, K. HONDA, T. MASUISHI, H. TANIGUCHI, S. KADOWAKI, T. URA, M. ANDO, M. TAIKA, K. MURO (Nagoya, Japan) .................................................. 5859


Relationship Between CA 19.9 and the Lewis Phenotype: Options to Improve Diagnostic Efficiency. M. PARRA-ROBERT, V.M. SANTOS, S.M. CANIS, X.F. PLA, J.M.A. FRADERA, R. MOLINA PORTO (Barcelona; Vilafranca del Penedès, Spain) ........................................................................................................................................................................ 5883


SUV_max-based Parameters of FDG-PET/CT Reliably Predict Pathologic Complete Response After Preoperative Hyperthermo-chemoradiotherapy in Rectal Cancer. H. MURATA, M. OKAMOTO, T. TAKAHASHI, M. MOTEGI, K. OGOSHI, H. SHOJI, M. ONISHI, Y. TAKAKUSAGI, N. OKONOGI, H. KAWAMURA, A. OKAZAKI, T. ASAO, H. KUWANO, T. NAKANO (Gunma; Chiba; Saitama, Japan) ........................................................................................................................................................................ 5909

Contents continued on the preceding page
Differential Mobility of Breast Cancer Cells and Normal Breast Epithelial Cells Under DC Electrophoresis and Electroosmosis. D. DUTTA, C. RUSSELL, J. KIM, S. CHANDRA (Kearney, NE, USA) ........................................................ 5733

Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of miR34a and miR200. M.I. KOKOURAKIS, E. KONTOMANOLIS, M. SOTIROPOLOU, A. MITRAKAS, E. DAPA, S. POUILIOU, E. SIVRIDIS, A. GIATROMANOLAKI (Alexandroupolis; Athens, Greece) .......................................................... 5739


Proteomic Identification of FLT3 and PCBP3 as Potential Prognostic Biomarkers for Pancreatic Cancer. M. GER, A. KAUPINIS, M. PETRULIONIS, B. KURLINKUS, J. CICENAS, A. SILEIKIS, M. VALIUS, K. STRUPAS (Vilnius, Lithuania; Bern, Switzerland; Vienna, Austria) .................................................................................................................. 5759

X-ray as Irradiation Alternative for K562 Feeder Cell Inactivation in Human Natural Killer Cell Expansion. G.H. KIM, H.-N. DANG, M.-T.T. PHAN, S.H. KWEON, S. CHUN, D. CHO (Seoul; Gyeongbuk; Pohang; Gwangju, Republic of Korea) ........................................................................................................ 5767

Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma. M. SANTONI, F. PIVA, U. DE GIORGI, A. MOSCA, U. BASSO, D. SANTINI, S. BUTI, C. LOLL, C. TERRONE, M. MARUZZO, M. IULIANI, M. BERSANELLI, A. CONTI, R. MAZZUCHELLI, R. MONTIRONI, L. BURATTINI, R. BERARDI (Ancona; Meldola; Novara; Padua; Rome; Parma; Genoa; Bressanone/Brissen, Italy) ........................................................................................................ 5773

High Efficacy of Intravenous Gimatecan on Human Tumor Xenografts. M. DE CESARE (Milan, Italy) ................................................................. 5783

Kisspeptin Inhibits Colorectal Cancer Cell Invasiveness by Activating PKR and PP2A. J.N. KIM, T.H. KIM, J.-H. YOON, S.-G. CHO (Pusan; Chungbuk, Republic of Korea) ........................................................................................................ 5791

4-Methylumbelliferone Decreases the Hyaluronan-rich Extracellular Matrix and Increases the Effectiveness of 5-Fluorouracil. E. YOSHIDA, D. KUDO, H. NAGASE, A. SUTO, H. SHIMODA, S. SUTO, I. KAKIZAKI, M. ENDO, K. HAKAMADA (Hirosaki, Japan) ........................................................................................................ 5799


Clinical Studies

Hard Palate Melanoma: A Population-based Analysis of Epidemiology and Survival Outcomes. C.M. ORANGES, G. SISTI, D. NASIOUDIS, M. TREMP, P.G. DI SUMMA, D.F. KALBERMATTEN, R.D. LARGO, D.J. SCHAFFER (Basel, Switzerland; New York, NY; Philadelphia, PA; Houston, TX, USA; Lausanne, Switzerland) ........................................................................................................ 5811

De Novo Myelodysplastic Syndrome and Subsequent Diagnosis of Primary Solid Tumors: Evidence from the National Cancer Institute 2001-2011. K. VICTORIA, I.G. FREEDMAN (Burlington, VT; New Haven, CT, USA) ........................................................................................................ 5819

Suboptimal Outcomes in Cutaneous Squamous Cell Cancer of the Head and Neck with Nodal Metastases. V. VARMA, N.M. WOODY, C. REDDY, N.P. JOSHI, J. GEIGER, D.J. ADELSTEIN, B.B. BURKEY, J. SCHARPF, B. PRENDES, E.D. LAMARRE, R. LORENZ, B. GASTMAN, B.V. MANYAM, S.A. KOYFMAN (Cleveland, OH, USA) ........................................................................................................ 5825
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer. O. YOUSSEF, A. KNUUTILA, P. PIIRILÄ, T. BÖHLING, V. SARHADI, S. KNUUTILA (Helsinki, Finland) ......................................................................................................................... 5627

Color-coded Imaging of the Circulating Tumor Cell Microenvironment. T. SATAKE, A. SUETSUGU, M. NAKAMURA, T. KUNISADA, M. SHIMIZU, S. SAJİ, H. MORIWAKI, R.M. HOFFMAN (Gifu, Japan; San Diego, CA, USA) .............................................................................................................................................. 5635

Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model. T. HIGUCHI, K. KAWAGUCHI, K. MIYAKE, Q. HAN, Y. TAN, H. OSHIRO, N. SUGISAWA, Z. ZHANG, S. RAzmjooei, N. YAMAMOTO, K. HAYASHI, H. KIMURA, S. MIWA, Y. KAWAMURA, S. KUSAKURA, A.S. SINGH, F.C. EILBER, S.R. SINGH, H. TSUCHIYA, R.M. HOFFMAN (San Diego; Santa Monica, CA; Frederick, MD, USA; Kanazawa, Japan) ........................................... 5639

Theranostics with Hybrid Liposomes in an Orthotopic Graft Model Mice of Breast Cancer. H. ICHIHARA, M. OKUMURA, K. TSUJIMURA, Y. MATSUMOTO (Kumamoto, Japan) .............................................................................................................. 5645

Cold Physical Plasma Selectively Elicits Apoptosis in Murine Pancreatic Cancer Cells In Vitro and In Ovo. K.R. LIEDTKE, S. DIEDRICH, O. PATI, E. FREUND, R. FLIEGER, C.D. HEIDECKE, I.I. PARTECKE, S. BEKESCHUS (Greifswald, Germany) .............................................................................................................. 5655


Relationship Between the Structure of Methoxylated and Hydroxylated Flavones and Their Antiproliferative Activity in HL60 Cells. S. KAWAI, Y. ISHIKAWA, Y. YOSHIZAWA (Saitama; Akita, Japan) ............................................................................................................................................. 5679

P-gp Inhibition by the Anti-psychotic Drug Pimozide Increases Apoptosis, as well as Expression of pRb and pH2AX in Highly Drug-resistant KBV20C Cells. J.Y. KIM, Y. PARK, B.-M. LEE, H.S. KIM, S. YOON (Siwon, Republic of Korea) ............................................................................................................................................. 5685

miR-3148 Is a Novel Onco-microRNA that Potentiates Tumor Growth In Vivo. T. AKAMINE, Y. MORODOMI, Y. HARADA, K. TERAISHI, T. TAGAWA, T. OKAMOTO, Y. MAEHARA, Y. YONEMITSU (Fukuoka, Japan) ............................................................................................................................................. 5693

IL-8-251T>A (rs4073) Polymorphism Is Associated with Prognosis in Gastric Cancer Patients. P. GONZALEZ-HORMAZABAL, S. ROMERO, M. MUSLEH, M. BUSTAMANTE, J. STAMBUK, R. PISANO, E. LANZARINI, H. CHIONG, J. ROJAS, V.G. CASTRO, L. JARA, Z. BERGER (Santiago, Chile) ............................................................................................................................................. 5703

Evaluation of Therapeutic Potential of Phenoxodiol, a Novel Isoflavone Analog, in Renal Cancer Cells. M. ISONO, A. SATO, TAKAKO ASANO, K. OKUBO, TOMOHiko ASANO (Tokorozawa, Japan) ............................................................................................................................................. 5709


Identification of Two Types of Stem Cells in Methylene Blue-stained Sections of Untreated and Diethylstilbestrol-treated Human Prostate Cancer and Their Characterization by Immunogold Localization of CD133. A.A. SINHA, M.J. WILSON (Minneapolis, MN, USA) ............................................................................................................................................. 5725

Contents continued on the preceding page